Leo Pharma takes hand eczema treatment into phase III

A new phase III study will investigate Leo Pharma’s drug delgocitinib as a cream for children and adolescents with severe chronic hand eczema.

Photo: Leo Pharma / PR

After success in a phase IIb study of adult patients, Leo Pharma is now turning its attention to children and adolescents between the ages 12 and 17 in order to expand the target group for delgocitinib, according to a registration on the Clinical Trials database.

The phase III trial will assess the safety and efficacy of delgocitinib in this age-restricted patient population with severe chronic hand eczema. The condition is diagnosed in cases when symptoms persist for more than three months or recur at least twice in one year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs